National Institute of General Medical Sciences

NOSI: Urgent Competitive Revisions to IDeA and NARCH Programs for SARS-CoV-2 Surveillance Studies

Hongwei Gao, M.D., Ph.D.
Division for Research Capacity Building, NIGMS

March 5, 2021



Goal and Requirements

Notice: NOT-GM-21-031

Goal: Increase SARS-CoV-2 genome sequence surveillance in IDeA states and Tribal Nations, which is severely lacking in available data, and improve tracking of variants

Research to be supported:

- Must propose sequencing studies, large study sample size strongly encouraged
- Must address one or more of the questions in the NOSI
- Should leverage established SARS-CoV-2 testing studies or programs, using FDA-authorized tests
- If studies among populations undergoing vaccination are proposed, MUST partner with an ongoing vaccination program
- Must provide the Letters of Support from any collaborating testing or vaccination programs

Eligibility

- One application allowed per parent IDeA-CTR, COBRE, INBRE, or NARCH grant
- Parent award must be active **(not in NCE)** when the NOSI supplement is submitted
- PI(s) on the application MUST be the same as on the parent award
  - PIs and their labs cannot receive research fund from IDeA awards. Research project must be led by another investigator(s).
- IDeA awards: no funding for non-IDeA states or foreign sites except as fee-for-service
- NARCH: foreign sites OK if the ancestral Tribal catchment area crosses national boundaries

Application and Submission Information

- Apply by March 31 using **PA-18-935** and enter NOT-GM-21-031 in Box 4b
- Must use FDA-authorized/approved diagnostic tests
- $500,000 maximum direct costs for 1-year budget
  - **Major portion is for genome sequencing and analysis**
  - No support to develop sequencing or testing technologies, no equipment over $5,000
- Commit to depositing sequence data into **Genbank**, where not prohibited

Key Elements of the Review Criteria

- Significance
  - Inform public health for control of the pandemic
- Investigators
  - Prior experience relevant to SARS-CoV-2, collaborations with testing/vaccination programs
- Research Design
  - Workflow, feasibility, relationship to parent grant
- Testing
  - Types of tests and sequencing protocols/resources
- Outcomes
  - Plans to report back to testing or vaccine program partners
- Data Sharing Plan
  - Access to sequences with metadata

Q&A Session